19 jun: Investeringsselskabet Artha Optimum A/S – ledende medarbejderes t..
19 jun: Ordinær generalforsamling - Harboes Bryggeri A/S
19-06-2019 17:36:00

Major Shareholder Announcement

Company Announcement

  • Major shareholder announcement for Genmab A/S

Copenhagen, Denmark; June 19, 2019 –

Genmab A/S (Nasdaq Copenhagen: GEN) announces under reference to Section 30 of the Danish Capital Markets Act that BlackRock, Inc. has informed us that, as of June 18, 2019, BlackRock, Inc. has increased their total ownership (indirectly owned shares and financial instruments) in Genmab A/S to 3,086,679 shares, which amounts to 5.00% of the share capital and voting rights in Genmab A/S.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 27

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jul
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
16
17 jul
I:SP500
På verdensplan vil næsten ingen acceptere økonomisk tilbageholdenhed til fordel for klimaet. En mill..
16
18 jul
 
Foranlediget lidt af debatten i den sidste uges tid, kommer her fredagsjoken: En investor her på EI..
15
20 jul
TEVA
Henningmaria: Casen omkring Teva har ikke ændret sig fundamentalt blot folks følelser pga verserende..
13
17 jul
I:SP500
Tøjindustrien står for 10 % af udslippet af klimagasser ifølge The Angry Clean Energy Guy. Det er me..
13
17 jul
 
Jeg er kvinde på 75 år og har haft afdragsfrit lån i 10 år. Min tidligere bankrådgiver, som vdste mi..
12
16 jul
VELO
At der er nogle som hiver lidt gevinst hjem. Fred være med det. Velo skal op i en helt anden kurs, n..
12
15 jul
BAVA
Tænk engang, med alt det du skriver om Bavarian og ebola vaccinen, så skulle man tro, at du bare ved..
12
18 jul
VELO
Jeg havde ligeledes håbet der var mulighed for at supplere lidt længere nede, men nu hedder det nok ..
11
15 jul
VELO
At optimisme er et advarselstegn er da hul i hovedet. Det kommer an på hvad optimismen bunder i. For..
11

Ugens regnskaber og nøgletal – Apple-regnskab, Amerikansk BNP & ECB-rente

22-07-2019 06:00:00
Mandag d. 22 juli RegnskaberHolland: Philips. Sydkorea: Samsung. USA: United Rentals, Halliburton Tirsdag d. 23 juli USA16.00 Eksisterende hussalg (juni)Tidligere: 5,34 mio.Konsensus: 5,34 mio. RegnskaberNorge: Norsk HydroFrankrig: HermésUSA: Apple, Coca Cola, United Technologies, Kimberly-Clark, Biogen, Hasbro, PaccarSchweiz: UBS Onsdag d. 24 juli Tyskland09.30  Manufacturing PMI (juli)Tidligere:..

Aktier/tendens: Ørsted tiltænkt helterolle i positiv aktieåbning

Relaterede nyheder
19-07-2019 08:09:28
Der er positive nyheder fra både den danske energikoncern Ørsted og biotekselskabet Genmab som oplæg til fredagens danske aktiehandel, hvor markedet før åbningen generelt er bagud i forhold til den stigning de amerikanske aktier præsterede i torsdagens handel.Sammen med stigende futures for både det amerikanske S&P 500-indeks og for det tyske DAX-indeks tidlig fredag morgen peger det mod en positi..

Danske Bank Q2: Kundeflugten fortsætter i udfordret bank

Relaterede nyheder
18-07-2019 11:06:22
Kunder siger fortsat farvel til Danske Bank - omend i et langsommere tempo end tidligere. I andet kvartal valgte 4300 Nemkonto-kunder at slukke for den forbindelse til banken, hvor de første seks måneder samlet gav en kundeafgang på 13.600 Nemkonto-kunder svarende til 1 pct. af bankens Nemkonto-kundebase.Det er fortsat bankens hvidvasksag i Estland, der danner ringe i vandet - men også sagen om pr..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank: Flere finanshuse sænker kursmål efter regnskab - NY
2
Ugens regnskaber og nøgletal – Apple-regnskab, Amerikansk BNP & ECB-rente
3
Nordea: Flere analytikere har ændret syn efter regnskab - NY2
4
Orphazyme forbereder ansøgning til amerikansk marked
5
Nordea/ABG: Anbefaling sænkes til hold og kursmål skæres til

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. juli 2019 07:33:09
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB6 - 2019-07-22 07:33:09 - 2019-07-22 07:33:09 - 1 - Website: OKAY